Biliary Atresia Therapeutics Market Global Report 2026

The biliary atresia therapeutics market size has grown strongly in recent years. It will grow from $1.02 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing awareness of pediatric liver disorders, improvements in kasai portoenterostomy outcomes, expansion of pediatric hepatology services, growing availability of liver transplantation programs, advancements in supportive nutritional care.

The biliary atresia therapeutics market size is expected to see strongly grown in the next few years. It will grow to $1.53 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of novel bile flow enhancing therapies, increasing adoption of personalized treatment approaches, expansion of pediatric specialty care infrastructure, rising investment in rare disease therapeutics, growth in advanced surgical intervention capabilities. Major trends in the forecast period include advancements in minimally invasive biliary surgery techniques, increasing adoption of early diagnosis and intervention programs, growing use of combination medication therapies for liver function support, expansion of pediatric liver transplantation programs, rising focus on post operative care and long term disease management.

The expansion of neonatal screening programs is expected to propel the growth of the biliary atresia therapeutics market going forward. Neonatal screening programs refer to systematic public health initiatives that test newborns shortly after birth to detect congenital, genetic, and metabolic disorders at an early stage. The expansion of neonatal screening programs is driven by increasing government initiatives and healthcare policies focused on the early detection and timely treatment of congenital and genetic disorders in newborns. The expansion of neonatal screening programs enables the earlier identification of affected newborns, allowing timely medical intervention and increasing the demand for effective treatment approaches to manage disease progression and improve clinical outcomes. For instance, in March 2026, according to touchENDOCRINOLOGY, a UK-based peer-reviewed journal, the UK National Screening Committee (UK NSC) launched a consultation on newborn screening for biliary atresia, a rare liver disease affecting approximately 1 in 17,000 babies in the UK, where early detection is critical because treatment within the first two months significantly improves outcomes, although uncertainty remains regarding the effectiveness of population-wide screening. Therefore, the expansion of neonatal screening programs is driving the growth of the biliary atresia therapeutics market.

Leading companies operating in the biliary atresia therapeutics market are focusing on advancing clinical trials to develop innovative treatment options, such as ileal bile acid transporter (IBAT) inhibitor-based therapies, to improve bile flow, reduce liver damage, and delay or prevent the need for liver transplantation in pediatric patients. IBAT inhibitor-based therapies refer to oral small-molecule drugs that work by blocking bile acid reabsorption in the intestine, thereby reducing toxic bile acid buildup in the liver, improving liver function, and supporting better clinical outcomes in cholestatic liver diseases such as biliary atresia. For example, in May 2023, Mirum Pharmaceuticals, a US-based biopharmaceutical company, announced the completion of enrollment in its Phase 2b EMBARK study evaluating LIVMARLI (maralixibat) oral solution for pediatric patients with biliary atresia. The study is a global, double-blind, randomized, placebo-controlled trial designed to assess the efficacy and safety of the therapy in infants who had previously undergone the Kasai procedure (hepatoportoenterostomy). The EMBARK study represents the first completed randomized clinical trial of an ileal bile acid transporter (IBAT) inhibitor for biliary atresia, with topline results expected in the second half of 2023, and is expected to provide important insights into improving liver function and delaying disease progression in this rare pediatric liver disorder.

In March 2023, Ipsen S.A., a France-based biopharmaceutical company, acquired Albireo Pharma Inc. for $952 million. Through this acquisition, Ipsen S.A. aimed to significantly expand its rare disease franchise, particularly in rare pediatric and cholestatic liver diseases, by adding innovative bile acid modulation therapies and strengthening its late-stage and commercial pipeline in hepatology. Albireo Pharma Inc. is a US-based biotechnology company that specializes in developing Bylvay (odevixibat) as a potential therapeutic for biliary atresia.

Major companies operating in the biliary atresia therapeutics market are Ipsen S.A.; Mirum Pharmaceuticals Inc.; CANbridge Pharmaceuticals Inc.

North America was the largest region in the biliary atresia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biliary atresia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biliary atresia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biliary atresia therapeutics market consists of sales of corticosteroids, antibiotics, antiviral drugs, bile acid therapies, immunosuppressants, nutritional supplements, liver support medications, and related therapeutic products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, healthcare providers, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The biliary atresia therapeutics market research report is one of a series of new reports that provides biliary atresia therapeutics market statistics, including biliary atresia therapeutics industry global market size, regional shares, competitors with a biliary atresia therapeutics market share, detailed biliary atresia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the biliary atresia therapeutics industry. This biliary atresia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.